Product image of Linagliptin/Metformin 1a Pharma (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin/Metformin 1a Pharma

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin/Metformin 1a Pharma (Metformin Hydrochloride, Linagliptin)

Linagliptin, the active ingredient in Linagliptin/Metformin 1a Pharma, is a DPP‑4 inhibitor presented as an oral tablet formulation for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient.

GNH India supplies Linagliptin/Metformin 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions globally.

Manufacturer / TM Owner

1a Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise.
  • Inadequate response to metformin alone: provides additional glucose‑lowering effect as part of combination therapy.
  • When combined with insulin or other antidiabetic agents: enhances insulin sensitivity and reduces post‑prandial glucose excursions.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises endogenous levels of incretin hormones (GLP‑1 and GIP) and thereby enhances glucose‑dependent insulin secretion while suppressing glucagon release. Metformin hydrochloride reduces hepatic gluconeogenesis, increases peripheral insulin sensitivity, and promotes glucose uptake in muscle, together producing a complementary reduction in blood glucose concentrations.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often transient.
  • Headache: mild cranial discomfort.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Vomiting: occasional emesis.
  • Abdominal pain: crampy discomfort.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin secretagogues.
  • Pancreatitis: acute inflammation of the pancreas.
  • Hepatic failure: marked liver enzyme elevation.
  • Allergic reactions: rash, angioedema, or anaphylaxis.
  • Renal dysfunction: worsening kidney function in susceptible patients.

Precautions & Warnings

Patients should be evaluated for renal and hepatic function before initiating therapy and monitored periodically.

  • Renal function monitoring: assess eGFR to ensure safe use.
  • Hepatic assessment: check liver enzymes for underlying disease.
  • Lactic acidosis risk: avoid in patients with severe heart failure or hypoxia.
  • Hypoglycemia vigilance: caution when used with sulfonylureas or insulin.
  • Cardiovascular status: monitor in patients with known cardiac disease.
  • Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin/Metformin may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

  • Concomitant insulin secretagogues (e.g., sulfonylureas): risk of severe hypoglycemia.
  • Iodinated contrast agents: may precipitate lactic acidosis in susceptible patients.
  • Strong CYP3A4 inhibitors: can increase linagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • NSAIDs: can impair renal function, increasing metformin accumulation.
  • ACE inhibitors/ARBs: monitor renal function and potassium levels.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • Warfarin: potential alteration of INR, requiring monitoring.

Frequently Asked Questions

Linagliptin/Metformin is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, particularly when diet, exercise, and metformin monotherapy do not achieve target glycemic levels.

Linagliptin blocks the DPP‑4 enzyme, which raises levels of incretin hormones (GLP‑1 and GIP). This enhances glucose‑dependent insulin secretion and reduces glucagon release, complementing metformin’s action on hepatic glucose production.

The specific dose is determined by the prescribing clinician based on the patient’s renal function, glycemic targets, and prior response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for Linagliptin in pregnancy are limited, and it is generally not recommended unless the potential benefit justifies the risk. Metformin is sometimes used during pregnancy under specialist guidance. Breastfeeding mothers should consult their healthcare provider before use.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with separate tablets of linagliptin and metformin, the fixed‑dose combination simplifies dosing and may improve adherence. Unlike some sulfonylureas, it carries a lower intrinsic risk of hypoglycemia, and unlike insulin, it is administered orally.

Store the tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture, heat, and direct sunlight to maintain stability throughout their shelf life.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their clinician.

Serious risks include lactic acidosis, especially in patients with renal impairment or heart failure, severe hypoglycemia when combined with insulin secretagogues, and rare cases of pancreatitis or allergic reactions. Prompt medical attention is required if any of these occur.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, acute or chronic metabolic acidosis, or a history of lactic acidosis should avoid this medication. Clinicians must assess suitability before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT